Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-sarcoma-family tumors
- 21 April 2000
- journal article
- clinical trial
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 34 (5) , 328-337
- https://doi.org/10.1002/(sici)1096-911x(200005)34:5<328::aid-mpo3>3.0.co;2-4
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- THE EWING FAMILY OF TUMORSPediatric Clinics of North America, 1997
- Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma.Journal of Clinical Oncology, 1993
- Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.Journal of Clinical Oncology, 1993
- Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.Journal of Clinical Oncology, 1990
- Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II.Journal of Clinical Oncology, 1990
- Ewing's sarcoma metastatic at diagnosis results and comparisons of two intergroup Ewing's sarcoma studiesCancer, 1990
- Therapy for localized Ewing's sarcoma of bone.Journal of Clinical Oncology, 1989
- Multidisciplinary treatment of primary Ewing's sarcoma of bone.A 6-year experience of a European cooperative trialCancer, 1988
- Prognostic factors in the treatment of Ewing's sarcomaRadiotherapy and Oncology, 1987
- Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.Journal of Clinical Oncology, 1987